Company intelligence / Profile preview

Virovek

Hayward, California, United Statesvirovek.com ↗

Ownership: Private
Development stage: Commercial

Overview

Virovek is a commercial-stage biotechnology company specializing in the development, optimization, and large-scale manufacturing of adeno-associated virus (AAV) and lentiviral vectors. Their patented BAC-to-AAV technology enables industry-leading yields for gene therapy applications. The company serves academic institutions, biotech firms, and pharmaceutical companies globally to support both basic research and clinical-stage drug development. They do not develop their own therapeutics but provide enabling technologies for others’ pipelines.

Modalities: Gene therapyViral vector (AAV)Lentiviral vectorBaculovirus-based production systemRecombinant protein (via viral vectors)
Industry: Drug Discovery Services

Partnerships

Collaborated with over 100 universities, non-profits, biotech/pharma companies worldwide.

Beyond the preview

Go deeper on Virovek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virovek.

Explore the full profile